| Year |
Citation |
Score |
| 2015 |
Soroceanu L, Matlaf L, Khan S, Akhavan A, Singer E, Bezrookove V, Decker S, Ghanny S, Hadaczek P, Bengtsson H, Ohlfest J, Luciani-Torres MG, Harkins L, Perry A, Guo H, et al. Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma. Cancer Research. 75: 3065-76. PMID 26239477 DOI: 10.1158/0008-5472.Can-14-3307 |
0.627 |
|
| 2015 |
Hexum JK, Becker CM, Kempema AM, Ohlfest JR, Largaespada DA, Harki DA. Parthenolide prodrug LC-1 slows growth of intracranial glioma. Bioorganic & Medicinal Chemistry Letters. 25: 2493-5. PMID 25978958 DOI: 10.1016/J.Bmcl.2015.04.058 |
0.397 |
|
| 2015 |
Renner DN, Jin F, Litterman AJ, Balgeman AJ, Hanson LM, Gamez JD, Chae M, Carlson BL, Sarkaria JN, Parney IF, Ohlfest JR, Pirko I, Pavelko KD, Johnson AJ. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. Plos One. 10: e0125565. PMID 25933216 DOI: 10.1371/journal.pone.0125565 |
0.415 |
|
| 2014 |
Magnus N, Meehan B, Garnier D, Hashemi M, Montermini L, Lee TH, Milsom C, Pawlinski R, Ohlfest J, Anderson M, Mackman N, Rak J. The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis. Biochemical and Biophysical Research Communications. 454: 262-8. PMID 25450387 DOI: 10.1016/J.Bbrc.2014.10.041 |
0.513 |
|
| 2014 |
Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, Blazar B, Ohlfest JR, Moertel C. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. Journal For Immunotherapy of Cancer. 2: 4. PMID 24829761 DOI: 10.1186/2051-1426-2-4 |
0.365 |
|
| 2014 |
Murphy KA, Erickson JR, Johnson CS, Seiler CE, Bedi J, Hu P, Pluhar GE, Epstein AL, Ohlfest JR. CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma. Journal of Immunology (Baltimore, Md. : 1950). 192: 224-33. PMID 24293627 DOI: 10.4049/jimmunol.1301633 |
0.349 |
|
| 2014 |
Calinescu A, Assi H, Kolb B, Koschmann C, Lowenstein PR, Ohlfest J, Castro MG. Abstract 187: Absence of S100A9 confers survival advantage in an aggressive de novo mouse model of glioblastoma multiforme Cancer Research. 74: 187-187. DOI: 10.1158/1538-7445.Am2014-187 |
0.531 |
|
| 2014 |
Pluhar L, Olin M, Goulart M, Andersen B, Hunt M, Ohlfest J. PM-17INTRACEREBRAL IFN-γ DOES NOT ENHANCE THE RESPONSE TO VACCINE IMMUNOTHERAPY FOR CANINE GLIOMA Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou268.17 |
0.446 |
|
| 2013 |
Ohlfest JR, Zellmer DM, Panyam J, Swaminathan SK, Oh S, Waldron NN, Toma S, Vallera DA. Immunotoxin targeting CD133(+) breast carcinoma cells. Drug Delivery and Translational Research. 3: 195-204. PMID 25787984 DOI: 10.1007/S13346-012-0066-2 |
0.326 |
|
| 2013 |
Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 477-89. PMID 24145359 DOI: 10.1097/01.Cji.0000436722.46675.4A |
0.396 |
|
| 2013 |
Bentley RT, Ober CP, Anderson KL, Feeney DA, Naughton JF, Ohlfest JR, O'Sullivan MG, Miller MA, Constable PD, Pluhar GE. Canine intracranial gliomas: relationship between magnetic resonance imaging criteria and tumor type and grade. Veterinary Journal (London, England : 1997). 198: 463-71. PMID 24051197 DOI: 10.1016/j.tvjl.2013.08.015 |
0.308 |
|
| 2013 |
Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. 171: 280-7. PMID 23871962 DOI: 10.1016/J.Jconrel.2013.07.014 |
0.32 |
|
| 2013 |
Andersen BM, Pluhar GE, Seiler CE, Goulart MR, SantaCruz KS, Schutten MM, Meints JP, O'Sullivan MG, Bentley RT, Packer RA, Thomovsky SA, Chen AV, Faissler D, Chen W, Hunt MA, ... ... Ohlfest JR, et al. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Research. 73: 2987-97. PMID 23471847 DOI: 10.1158/0008-5472.Can-12-3366 |
0.375 |
|
| 2013 |
Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, Salazar AM, Olin MR. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. Journal of Immunology (Baltimore, Md. : 1950). 190: 613-20. PMID 23248259 DOI: 10.4049/Jimmunol.1201557 |
0.314 |
|
| 2013 |
Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 33-9. PMID 23014761 DOI: 10.1124/dmd.112.048322 |
0.389 |
|
| 2013 |
Goulart M, Pluhar E, Andersen B, Seiler C, Hunt M, O'Sullivan G, Zhang Z, Ohlfest J. Abstract B20: Immunotherapy as treatment for dogs with glioma. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B20 |
0.485 |
|
| 2012 |
Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, Decker SA, Santacruz KS, Pokorny JL, Sarkaria JN, Elmquist WF, Ohlfest JR. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Molecular Cancer Therapeutics. 11: 2183-92. PMID 22891038 DOI: 10.1158/1535-7163.Mct-12-0552 |
0.644 |
|
| 2012 |
Andersen BM, Ohlfest JR. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Letters. 325: 155-64. PMID 22809568 DOI: 10.1016/J.Canlet.2012.07.012 |
0.329 |
|
| 2012 |
Murphy KA, Lechner MG, Popescu FE, Bedi J, Decker SA, Hu P, Erickson JR, O'Sullivan MG, Swier L, Salazar AM, Olin MR, Epstein AL, Ohlfest JR. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4657-68. PMID 22781551 DOI: 10.1158/1078-0432.Ccr-12-0990 |
0.603 |
|
| 2012 |
Moertel CL, Olin M, Dahlheimer T, Gustafson M, Sumstand D, McKenna D, Low W, Nascene D, Dietz A, Ohlfest J. Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells. Journal of Clinical Oncology. 30: 2546-2546. DOI: 10.1200/Jco.2012.30.15_Suppl.2546 |
0.306 |
|
| 2012 |
Ohkuri T, Kosaka A, Ikeura M, Litterman A, Ohlfest J, Okada H. Abstract 3507: Type 17-1-CD8+ T cells (Tc17-1) as potent effector cells for immunotherapy of brain tumors Cancer Research. 72: 3507-3507. DOI: 10.1158/1538-7445.Am2012-3507 |
0.472 |
|
| 2011 |
Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver AL, Robertson PT, Liang X, Chen W, Parney IF, Hunt MA, Blazar BR, Ohlfest JR. Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Research. 71: 6583-9. PMID 21908554 DOI: 10.1158/0008-5472.Can-11-1166 |
0.303 |
|
| 2011 |
Xiong Z, Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 264-9. PMID 21389872 DOI: 10.1097/CJI.0b013e318209eed4 |
0.337 |
|
| 2011 |
Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Research. 71: 2664-74. PMID 21324923 DOI: 10.1158/0008-5472.Can-10-3055 |
0.634 |
|
| 2011 |
Pavel H, Ajeawung N, Faure R, Poirier D, Kamnasaran D, Ajeawung N, Joshi H, Kamnasaran D, Poirier D, Ajeawung N, Kamnasaran D, Lun X, Zemp F, Sun B, Stechishin O, ... ... Ohlfest J, ... ... Ohlfest JR, et al. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 13: iii107-iii120. DOI: 10.1093/Neuonc/Nor158 |
0.331 |
|
| 2010 |
Bodempudi V, Ohlfest JR, Terai K, Zamora EA, Vogel RI, Gupta K, Hebbel RP, Dudek AZ. Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. Cancer Gene Therapy. 17: 855-63. PMID 20725100 DOI: 10.1038/Cgt.2010.42 |
0.409 |
|
| 2010 |
Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Moore PF, Avalos J, Young JD, Khan D, Donelson R, Pluhar GE, Ohlfest JR, Wawrowsky K, Lowenstein PR, et al. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. Plos One. 5: e11074. PMID 20552015 DOI: 10.1371/Journal.Pone.0011074 |
0.352 |
|
| 2010 |
Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, Kato H, Bondy ML, Ohlfest JR, Okada H. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3409-19. PMID 20472682 DOI: 10.1158/1078-0432.Ccr-10-0644 |
0.575 |
|
| 2010 |
Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. The Journal of Pharmacology and Experimental Therapeutics. 334: 147-55. PMID 20421331 DOI: 10.1124/jpet.110.167601 |
0.3 |
|
| 2010 |
Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine. 28: 3371-8. PMID 20197146 DOI: 10.1016/J.Vaccine.2010.02.082 |
0.319 |
|
| 2009 |
Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen H, Vallera DA. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. Journal of Neuro-Oncology. 95: 331-42. PMID 19517064 DOI: 10.1007/s11060-009-9932-2 |
0.371 |
|
| 2009 |
Wiesner SM, Decker SA, Larson JD, Ericson K, Forster C, Gallardo JL, Long C, Demorest ZL, Zamora EA, Low WC, SantaCruz K, Largaespada DA, Ohlfest JR. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Research. 69: 431-9. PMID 19147555 DOI: 10.1158/0008-5472.Can-08-1800 |
0.652 |
|
| 2009 |
Murphy KA, Forster CL, Seiler C, Ohlfest J. Brain tumor-infiltrating plasma cells or circulating antibody account for endogenous reactivity to secondary antibody Journal of Histotechnology. 32: 175-178. DOI: 10.1179/His.2009.32.4.175 |
0.417 |
|
| 2008 |
Low W, Burns T, Verfaillie C, Hackett P, Whitley C, Nan Z, Xiao F, Belur L, Demorest Z, Wolf D, Ohlfest J, McIvor S. 64. Targeting neural stem cells in the mammalian brain with intraventricular injections of lenti, AAV5, or Sleeping Beauty vectors Molecular Genetics and Metabolism. 93: 30. DOI: 10.1016/J.Ymgme.2007.10.076 |
0.319 |
|
| 2007 |
Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 789-97. PMID 18049330 DOI: 10.1097/Cji.0B013E318155A0F6 |
0.328 |
|
| 2007 |
Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR, Castro MG. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. Journal of Neuro-Oncology. 85: 133-48. PMID 17874037 DOI: 10.1007/S11060-007-9400-9 |
0.426 |
|
| 2007 |
Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AK, Xiong W, Liu C, Mondkar S, Kuoy W, Kang T, McNeil EA, Freese AB, Ohlfest JR, et al. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro-Oncology. 9: 245-58. PMID 17522335 DOI: 10.1215/15228517-2007-012 |
0.327 |
|
| 2007 |
Candolfi M, Kroeger KM, Pluhar GE, Bergeron J, Puntel M, Curtin JF, McNiel EA, Freese AB, Ohlfest JR, Moore P, Lowenstein PR, Castro MG. Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery. 60: 167-77; discussion 1. PMID 17228266 DOI: 10.1227/01.Neu.0000249210.89096.6C |
0.338 |
|
| 2005 |
Wiesner SM, Freese A, Ohlfest JR. Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies. Neurosurgical Focus. 19: E3. PMID 16241105 DOI: 10.3171/Foc.2005.19.4.4 |
0.336 |
|
| 2005 |
Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, Scappaticci FA, Saplis RJ, Ekker SC, Low WC, Freese AB, Largaespada DA. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 778-88. PMID 16150649 DOI: 10.1016/J.Ymthe.2005.07.689 |
0.377 |
|
| 2004 |
Ohlfest JR, Lobitz PD, Perkinson SG, Largaespada DA. Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 260-8. PMID 15294173 DOI: 10.1016/J.Ymthe.2004.05.005 |
0.344 |
|
| Show low-probability matches. |